Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America

Alessandra Vecchié, MD; Juan G. Chiabrando, MD; Megan S. Dell, BSBME; Aldo Bonaventura, MD; Adolfo G. Mauro, PhD; George Wohlford, PharmD; Benjamin W. Van Tassell, PharmD; Daniel H. Berrocal, MD, PhD; Fabrizio Montecucco, MD, PhD; Anna Beutler, MD; John F. Paolini, MD, PhD; Tamas S. Gal, PhD; and Antonio Abbate, MD, PhD

BACKGROUND: Acute pericarditis is the most common presentation of pericardial diseases. Although generally benign, complications such as constrictive pericarditis, cardiac tamponade, and recurrence can occur.

RESEARCH QUESTION: What are the clinical factors associated with adverse outcomes in acute pericarditis?

STUDY DESIGN AND METHODS: We used an informatics-based search engine to search for International Classification of Diseases codes related to pericardial disease between January 1, 2009 and November 14, 2018 and then extracted clinical information, including only patients meeting the European Society of Cardiology criteria for acute pericarditis. We then evaluated the predictive value of clinical characteristics for adverse outcomes (cardiac tamponade, constrictive pericarditis, failure of therapy, recurrences, or death).

RESULTS: We identified 240 patients with a first episode of pericarditis (51 [34-62] years, 56% males and 50% white). Pericarditis was determined to be idiopathic in 126 (53%) cases and related to cardiac injury in 79 (33%). During a median follow-up time of 179 (20-450) days, 82 (34%) patients experienced at least one adverse outcome. Subacute presentation was an independent predictor of adverse outcomes. Patients with postcardiac injury pericarditis had a lower incidence in the composite of failure of treatment and recurrence (13% vs 26%; \( P = .022 \)) compared with patients with idiopathic pericarditis. Troponin I measurements were obtained in 167 patients (70%). Elevated troponin I levels were associated with lower incidence of recurrences (4% vs 17%; \( P = .024 \)) and of the composite outcome (13% vs 36%; \( P = .004 \)).

INTERPRETATION: Acute pericarditis is associated with at least one adverse outcome in 34% of patients. Subacute presentation and idiopathic etiology are associated with higher incidence of adverse outcomes, whereas elevated troponin I levels identify a group with reduced risk of recurrences.

KEY WORDS: acute pericarditis; recurrence; subacute presentation; therapy failure; troponin I

ABBREVIATIONS: AMI = acute myocardial infarction; ESC = European Society of Cardiology; ICD = International Statistical Classification of Diseases and Related Health Problems

AFFILIATIONS: From the Pauley Heart Center (Drs Vecchié, Chiabrando, Bonaventura, Mauro, and Abbate), Virginia Commonwealth University, Richmond, VA; First Clinic of Internal Medicine, Department of Internal Medicine (Drs Vecchié and Bonaventura),
Acute pericarditis is the most common presentation of pericardial diseases affecting subjects of both sexes and represents an important cause of morbidity, especially in patients experiencing recurrence. Epidemiological data are scarce, possibly because of the low sensitivity of diagnostic methods. Previous observational studies have reported a prevalence of acute pericarditis of 27.7 cases per 100,000 person-years in an urban area of Northern Italy. A large epidemiologic study conducted in Finland reported an incidence of 4.52 per 100,000 person-years for men and 2.11 per 100,000 person-years for women. TB is the most common cause in low-income countries, and idiopathic pericarditis is the most reported cause in developed countries. However, postcardiac injury syndrome is a growing cause of pericarditis, likely because of an increase in the number of interventional procedures and cardiac surgeries. Idiopathic pericarditis has a poorly studied pathophysiology and is considered to be the result of auto-inflammation possibly related to an immune response to viral infections.

Patients who have a favorable response to antiinflammatory drugs generally have a good prognosis. However, complications such as cardiac tamponade, constrictive pericarditis, and episodes of recurrence may occur. In addition, adverse drug reactions are common in the currently recommended treatment regimens. In an attempt to risk stratify patients with chest pain, cardiac biomarkers (ie, troponin T and I) are routinely measured. The prognostic role of these cardiac biomarkers in pericarditis is, however, less well established.

We aimed to analyze the clinical characteristics of patients presenting with acute pericarditis at the Virginia Commonwealth University Medical Center (Richmond, VA), a large urban hospital in the United States, and to gain insights into clinical features associated with an increased risk of adverse outcomes, such as recurrences, constrictive pericarditis, and cardiac tamponade.

Patients and Methods

Study Design

We conducted a retrospective review employing an informatics engine-based search (TriNetX). TriNetX is a global federated network of health research, providing access to data from electronic medical records of patients in large health-care organizations in the United States. For the initial subject identification, the International Statistical Classification of Diseases and Related Health Problems (ICD)-10 code related to acute pericarditis diagnosis (330) was used. TriNetX automatically includes the corresponding ICD-9 codes. We identified 494 adult patients between January 1, 2009 and November 14, 2018, and two experienced physicians performed a chart review through electronic health records to complete a database including 240 patients meeting the European Society of Cardiology (ESC) criteria for acute pericarditis (e-Fig 1). According to guidelines, the diagnosis of acute pericarditis requires at least two of the four following criteria: (1) pericardial chest pain; (2) pericardial rubs; (3) new ST-elevation or PR depression on ECG; (4) new or worsening pericardial effusion. Inpatients and outpatients were both included. The database contained relevant demographic data, clinical characteristics, treatments received, and adverse outcomes. All data, including ECG and echocardiographic data, were reviewed by at least two cardiologists before entry into the final database. Disagreements on findings or readings were resolved through discussion. The study complied with the Declaration of Helsinki. The chart review was approved by the local Institutional Review Board.

Study End points and Definitions

The primary goal was to identify predictors of the composite adverse outcome (tamponade, constrictive pericarditis, failure of treatment, clinical recurrences, or death) in a large cohort of patients with acute pericarditis. Secondary aims were to provide an overview of the pericarditis causes and to compare clinical and laboratory profiles among subgroups (eg, with or without adverse outcomes).

Patients were identified as having an acute event if they met the 2015 ESC guideline criteria for acute pericarditis. A recurrent episode requires new signs and symptoms of pericardial inflammation after a symptom-free interval of 4 to 6 weeks. Subacute pericarditis was defined as an event developing in an interval from 6 weeks to 3 months. Constrictive pericarditis was defined by the development of hemodynamic diastolic impairment due to a chronic inflammation or thickening of the pericardium diagnosed at echocardiography, cardiac magnetic resonance, or surgical biopsy.
Tamponade was identified as a pericardial effusion, resulting in hemodynamic compromise, diagnosed with echocardiographic criteria. We considered failure of treatment as the persistence of symptoms regardless of antiinflammatory treatment for >4-6 weeks. A severe pericardial effusion during an echocardiogram was defined as the presence of an echo-free space ≥20 mm according to the classification of Imazio et al20 and Weitzman et al.21 Heart failure at presentation was defined as having signs and symptoms of volume overload, or the need to initiate treatment with a loop diuretic. Meeting any of the following constituted the composite end point of adverse outcomes (“composite outcome”): failure of treatment, recurrence of pericarditis, cardiac tamponade, constrictive pericarditis, or death.

Statistical Analysis
Continuous data were reported as median and interquartile range, and data were compared with the Mann-Whitney U test.

Results
Clinical Characteristics of the Patients
A total of 240 patients were found to meet acute pericarditis criteria, and the characteristics at the time of presentation are summarized in Table 1. The median age of the cohort was 51 (34-62) years, with 135 (56%) men, and 121 (50.4%) self-defined whites and 100 (41.7%) blacks. Two hundred twenty (92%) patients had pericardial chest pain, 43 (18%) pericardial rubs, 107 (47%) pericardial effusion, and 128 (53%) ECG alterations (71 [30%] PR depression and 104 [43%] ST elevation). Idiopathic pericarditis was found to be the most common diagnosis (126, [52.5%]). Postcardiac injury was the second most frequent cause of pericarditis (79 [32.9%]; Fig 1A). Among patients with postcardiac injury pericarditis, four (5%) had a chest trauma, 11 (14%) an acute myocardial infarction (AMI), 32 (41%) a catheter ablation, and one (1%) thoracoscopic ablation, six (8%) a pacemaker implantation, 11 (14%) surgery for valve repair or replacement, and four (5%) intervention for left appendage exclusion. Eleven (14%) patients had a cardiac bypass surgery, of which three happened after AMI. Ten (13%) patients underwent a percutaneous coronary intervention, eight of which occurred after AMI.

Patients presented with a history of cardiovascular disease (chronic heart failure, atrial fibrillation, myocardial infarction, hypertension) in 35% of cases, diabetes in 20%, and autoimmune disease in 10%, with approximately 20% having recently undergone a cardiac procedure.

A small number of patients (12 [5.1%]) had a subacute presentation. A total of 49 patients (20.6%) were found to have a severe pericardial effusion, and 31 (13%) had tamponade.

Laboratory tests showed abnormal inflammatory biomarkers (C-reactive protein, 10 [1.6-18.6] mg/dL; and erythrocyte sedimentation rate, 52 [23-88] mm/h) for those with data available (n = 72, 30%; and n = 61, 25.4%, respectively).

A troponin I measurement during the first pericarditis episode was available for 167 (70%) individuals. When comparing patients with and without troponin I determination, differences were found in the frequency of recent cardiac procedures and ECG alterations, suggesting that troponin was measured to aid in the diagnosis or exclude myocardial injury (e-Table 1). Of the 167 patients who had troponin I measurements at arrival, 46 (27.5%) had elevation in serum troponin I levels (≥ 0.20 ng/mL).

Nonsteroidal antiinflammatory drugs (NSAIDs) were used in 169 (70.7%) cases, colchicine in 152 (63.6%), and glucocorticoids in 29 (12.2%). A total of 189 (80.8%) patients were hospitalized at the time of diagnosis, and 42 (17.5%) required an invasive procedure related to the pericardial disease (pericardiocentesis [n = 27, 11.3%], pericardiectomy [n = 8, 3.3%], or pericardial window [n = 7, 2.9%]).

Adverse Outcomes
The cohort had a median follow-up time at our institution of 179 (20-450) days after the qualifying episode, and 82 (34.2%) patients experienced at least one of the following adverse outcomes: 38 (15.8%) developed recurrent pericarditis, 31 (13%) tamponade, nine (3.8%) constrictive pericarditis, 17 (7.2%) failure of treatment,
and nine (3.8) died (Fig 1B). Rehospitalization for any reason occurred in 90 subjects (37.7%).

No significant differences in baseline demographic characteristics or pericarditis etiology at qualifying event were found when comparing those with and without

### TABLE 1
#### Characteristics of the Overall Cohort

| Characteristics                                      | Overall Cohort (n = 240) |
|------------------------------------------------------|--------------------------|
| Demographics                                         |                          |
| Male sex                                             | 135 (56)                 |
| Age, y                                               | 51 [34-62]               |
| Race                                                 |                          |
| White                                                | 121 (50.4)               |
| Black                                                | 100 (41.7)               |
| Othera                                               | 19 (7.9)                 |
| BMI                                                  | 28 [24-32]               |
| Medical history                                      |                          |
| Hypertension                                         | 37 (15.4)                |
| Diabetes                                             | 51 (21.3)                |
| Dyslipidemia                                         | 79 (32.9)                |
| Coronary artery disease                              | 52 (21.7)                |
| Chronic heart failure                                | 51 (21.3)                |
| Stroke/transient ischemic attack                     | 13 (5.4)                 |
| Atrial fibrillation                                  | 63 (26.3)                |
| Myocardial infarction                                | 33 (13.8)                |
| Active smokers                                       | 77 (32.2)                |
| Autoimmune diseases                                  | 24 (10.0)                |
| TB                                                   | 2 (0.8)                  |
| Chest radiation                                      | 8 (3.3)                  |
| Neoplastic diseases                                  | 30 (12.5)                |
| Severe chronic kidney disease                        | 44 (18.4)                |
| Chest trauma                                         | 4 (1.7)                  |
| Recent cardiac procedure                             |                          |
| Percutaneous coronary intervention                   | 7 (2.9)                  |
| Pacemaker/cardiac ablation                           | 24 (10.0)                |
| Cardiac surgery                                      | 19 (7.9)                 |
| Therapies                                            |                          |
| Immunosuppression                                    | 15 (6.3)                 |
| High dose corticosteroids                            | 9 (3.8)                  |
| Oral anticoagulation                                 | 27 (11.3)                |
| Etiology                                             |                          |
| Idiopathic                                           | 126 (52.5)               |
| Postcardiac injury                                   | 79 (32.9)                |
| Other                                                | 35 (14.5)                |
| Clinical presentation                                |                          |
| Fever                                                | 21 (8.9)                 |
| Subacute presentation                                | 12 (5.1)                 |
| Trauma                                               | 5 (2.1)                  |
| Pericardial effusion                                 | 107 (47%)                |
| Severe pericardial effusion                          | 49 (20.6)                |
| Heart failure                                        | 43 (18.1)                |
| Chest pain                                           | 220 (93.2)               |

#### TABLE 1 (Continued)

| Characteristics                                      | Overall Cohort (n = 240) |
|------------------------------------------------------|--------------------------|
| Cardiac examination                                  |                          |
| Pericardial rub                                      | 43 (18.5)                |
| Pulsus paradoxus                                     | 10 (4.3)                 |
| Kussmaul sign                                        | 4 (1.7)                  |
| ECG                                                  |                          |
| PR depression                                        | 70 (30.6)                |
| ST elevation                                         | 104 (45.4)               |
| T wave inversion                                     | 57 (24.9)                |
| Laboratory                                           |                          |
| WBC, No. ×10⁹/mL                                     | 9.4 [6.7-12.3]           |
| Neutrophils, No. ×10⁹/mL                             | 6.7 [4.2-9.5]            |
| Lymphocyte, No. ×10⁹/mL                              | 1.6 [1.0-2.0]            |
| Hemoglobin, g/dL                                     | 12.1 [10.4-13.5]         |
| Platelets, No. ×10³/mL                               | 240 [177-325]            |
| Creatinine, mg/dL                                    | 0.89 [0.72-1.1]          |
| C-reactive protein, mg/dL                            | 10.0 [1.6-18.6]          |
| Erythrocyte sedimentation rate, mm/h                 | 52 [23-88]               |
| Troponin ≥ 0.20 ng/mL                                | 46 (27.5)                |
| Treatment at presentation                            |                          |
| Nonsteroidal antiinflammatory drugs                  | 169 (70.7)               |
| Colchicine                                           | 152 (63.6)               |
| Glucocorticoids                                      | 29 (12.2)                |
| Surgical procedure                                   |                          |
| Pericardiectomy                                      | 8 (3.3)                  |
| Pericardial window                                   | 7 (2.9)                  |
| Pericardiocentesis                                   | 27 (11.3)                |
| Outcomes                                             |                          |
| Composite outcomeb                                   | 82 (34.2)                |
| Treatment failure                                    | 17 (7.2)                 |
| Recurrent pericarditis                               | 38 (15.8)                |
| Cardiac tamponade                                    | 31 (13.0)                |
| Constrictive pericarditis                            | 9 (3.8)                  |
| Death                                                | 9 (3.8)                  |
| Rehospitalization for any cause                      | 90 (37.7)                |

The data are presented as No. (%) of all cases or as median [interquartile range].

aOther includes Asian, Native American, Hispanic, or not specified.

bComposite end point defined as the presence of any of the following: failure of treatment, recurrences, cardiac tamponade, constrictive pericarditis, or death.
adverse outcomes (Table 2). Subjects with adverse outcomes were more likely to have had a subacute presentation (12.2% vs 1.3%; OR, 10.7; 95% CI, 2.3-50.1; \( P = .001 \)). Among those with troponin I sampling, subjects who did not experience any adverse outcome presented more frequently with elevated levels of the biomarker (25.3% vs 7.3%; OR, .27; 95% CI, 0.11-0.69; \( P = .004 \)). In addition, patients without adverse outcomes were also more likely to have been prescribed colchicine (69% vs 52.4%; OR, 0.51; 95% CI, 0.29-0.88; \( P = .023 \)). No significant difference was found in the nonsteroidal antiinflammatory drugs or glucocorticoids prescription rates.

In a logistic regression model, elevated troponin I levels were found to be predictive of lower incidence of the composite outcome during the follow-up (OR, 0.27; 95% CI, 0.11-0.69; \( P = .006 \)), even after adjustment for history of myocardial infarction, oral anticoagulation, subacute presentation, hemoglobin value, and treatment with colchicine (adjusted OR, 0.33; 95% CI, 0.12-0.93; \( P = .035 \)) (Fig 2, e-Table 2). Subacute presentation was found to be predictive for the composite adverse outcome (unadjusted OR, 10.69; 95% CI, 2.28-50.07; \( P = .003 \), and adjusted OR, 15.02; 95% CI, 1.85-138.65; \( P = .013 \)) (Fig 2, e-Table 2).

Comparison Between Idiopathic and Postcardiac Injury Pericarditis

When compared with patients with idiopathic pericarditis, those with postcardiac injury pericarditis were older (61 [50-71] vs 48 [34-58] years; \( P < .001 \), e-Table 3). A significantly greater number of blacks were found in the idiopathic pericarditis group compared with the postcardiac injury group (70 [55.6%] vs 14 [17.7%]; \( P < .001 \)). The prevalence of other cardiovascular diseases was higher in patients with postcardiac injury pericarditis who also showed a higher prevalence of heart failure at presentation compared with idiopathic pericarditis patients (20 [25.3%] vs 13 [10.3%]; \( P = .006 \)). A higher number of patients with postcardiac injury had elevation in troponin I levels (22 [27.8%] vs 9 [7.1%]; \( P < .001 \)). Finally, there was a higher incidence of the combined failure of treatment or clinical recurrences in patients with idiopathic pericarditis compared with those with postcardiac injury (33 [26.2%] vs 10 [12.7%]; OR 2.44 [1.13-5.30]; \( P = .022 \)) (Fig 3A).

Troponin I Level as Prognostic Marker

Subjects with elevated troponin I (\( \geq 0.20 \) ng/mL) were more likely to have a history of other cardiovascular diseases (e-Table 4). Patients with abnormal troponin I values also presented more frequently with heart failure symptoms at the onset of pericarditis (14 [30.4%] vs 18 [14.9%]; \( P = .028 \)), experienced fewer recurrent events (2 [4.3%] vs 20 [16.5%]; \( P = .23 \); 95% CI, 0.05-1.03; \( P = .041 \)) and had a reduced occurrence of the composite adverse outcome (6 [13%] vs 43 [35.5%]; OR, 0.27; 95% CI, 0.11-0.69; \( P = .004 \)) (Fig 3B).

Discussion

Acute pericarditis is a relatively common, often unrecognized clinical condition that has significant
| Characteristics                                      | Uncomplicated Cases (n = 158) | Patients With Adverse Outcome (n = 82) |
|-----------------------------------------------------|-------------------------------|--------------------------------------|
| **Demographics**                                    |                               |                                      |
| Male sex                                            | 95 (50.1)                     | 40 (48.8)                            |
| Age, y                                              | 51 [35-62]                    | 53 [32-65]                           |
| Race                                                |                               |                                      |
| White                                               | 74 (46.8)                     | 47 (57.3)                            |
| Black                                               | 70 (44.9)                     | 29 (35.4)                            |
| Other                                               | 13 (8.2)                      | 6 (7.3)                              |
| BMI                                                 | 28 [24-32]                    | 28 [23-34]                           |
| **Medical history**                                 |                               |                                      |
| Hypertension                                        | 81 (51.3)                     | 45 (54.9)                            |
| Diabetes                                            | 37 (23.4)                     | 14 (17.1)                            |
| Dyslipidemia                                        | 51 (32.3)                     | 28 (34.1)                            |
| Coronary artery disease                             | 36 (22.8)                     | 16 (19.5)                            |
| Chronic heart failure                               | 32 (20.3)                     | 19 (23.2)                            |
| Stroke/transient ischemic attack                    | 9 (5.7)                       | 4 (4.9)                              |
| Atrial fibrillation                                 | 43 (27.2)                     | 20 (24.4)                            |
| Previous myocardial infarction                      | 27 (17.1)                     | 6 (7.3)                              |
| Active smokers                                      | 55 (34.8)                     | 22 (26.8)                            |
| Autoimmune diseases                                 | 12 (7.6)                      | 12 (14.6)                            |
| TB                                                  | 2 (1.3)                       | ...                                  |
| Chest radiation                                     | 5 (3.2)                       | 3 (3.7)                              |
| Neoplastic diseases                                 | 15 (9.5)                      | 15 (18.3)                            |
| Severe chronic kidney disease                       | 23 (14.6)                     | 21 (25.6)                            |
| Chest trauma                                        | 4 (2.5)                       | 2 (2.4)                              |
| Recent cardiac procedure                            |                               |                                      |
| Percutaneous coronary intervention                  | 5 (3.2)                       | 2 (2.4)                              |
| Pacemaker/cardiac ablation                          | 17 (10.8)                     | 7 (8.5)                              |
| Cardiac surgery                                     | 13 (8.2)                      | 6 (7.3)                              |
| **Therapies**                                       |                               |                                      |
| Immunosuppression                                   | 9 (5.7)                       | 6 (7.3)                              |
| High-dose corticosteroids                           | 4 (2.5)                       | 5 (6.1)                              |
| Oral anticoagulation                                | 24 (15.2)                     | 3 (3.7)                              |
| **Etiology**                                        |                               |                                      |
| Idiopathic                                          | 82 (49.7)                     | 44 (58.7)                            |
| Postcardiac injury                                  | 61 (37.0)                     | 18 (24.0)                            |
| Other                                               | 22 (13.3)                     | 13 (10.6)                            |
| **Clinical presentation**                           |                               |                                      |
| Fever                                               | 15 (9.5)                      | 6 (7.3)                              |
| Subacute presentation                               | 2 (1.3)                       | 10 (12.2)                            |
| Trauma                                              | 4 (2.5)                       | 5 (6.1)                              |
| Severe (>20 mm) pericardial effusion                | 14 (8.9)                      | 35 (42.7)                            |
| Heart failure                                       | 27 (17.1)                     | 16 (19.5)                            |
| Chest pain                                          | 150 (94.9)                    | 70 (85.4)                            |
complications. Although several large-scale epidemiologic studies on the incidence and prevalence have been conducted, a detailed characterization of the condition and its complications is lacking. In the current study, including a mixed population of whites and blacks served at an urban hospital in the United States, we found that (1) subacute presentation is independently associated with a greater risk for the development of adverse outcomes; (2) patients with idiopathic pericarditis more frequently experience treatment failure or clinical recurrences, when compared with postcardiac injury pericarditis; (3) for patients with troponin I obtained, those with elevated troponin I levels were less likely to experience adverse outcomes, such as clinical recurrences.

Subacute, or delayed-onset, presentation had already been reported as an unfavorable prognostic factor for the development of adverse outcomes in acute pericarditis. The early recognition of acute pericarditis may be important, because timely treatment may reduce both acute inflammatory symptoms and the incidence of recurrence. A delay in treatment due to a subacute presentation may consolidate the inflammation of the pericardium and markedly increase the complication rate. The definition of subacute presentation, however, remains imprecise and without a clear determination of the time window. Subacute presentation also may be a surrogate for a specific cause of pericarditis that is not identified in these studies, that has a more subtle clinical course yet a higher risk of recurrence. Further prospective clinical studies may help better define appropriate time windows for the pathophysiology and identification of risk factors.

Hemoglobin has been found as a protective factor in our cohort. This finding is novel and unreported in the literature. Inflammation is known to reduce the activity

| TABLE 2 | (Continued) |
| Characteristics | Uncomplicated Cases (n = 158) | Patients With Adverse Outcome (n = 82) |
| Cardiac examination | | |
| Pericardial rub | 31 (19.6) | 12 (14.6) |
| Pulsus paradoxus | 3 (1.9) | 7 (8.5) |
| Kussmaul sign | 3 (1.9) | 4 (4.9) |
| ECG | | |
| PR depression | 48 (30.4) | 23 (28) |
| ST elevation | 73 (46.2) | 31 (37.8) |
| T wave inversion | 41 (25.9) | 17 (20.7) |
| Laboratory | | |
| WBC, No. ×10^9/mL | 9.0 [6.5-12.5] | 9.7 [7.3-11.9] |
| Neutrophils, No. ×10^9/mL | 6.65 [4.13-9.8] | 7.10 [4.45-8.95] |
| Lymphocyte, No. ×10^9/mL | 1.65 [1-2.3] | 1.3 [1-1.9] |
| Neutrophil/lymphocyte ratio | 3.97 [2.31-7.07] | 4.80 [3.22-7.98] |
| Hemoglobin, g/dL | 12.4 [10.7-14] | 11.4 [9-13.1] |
| Platelets, No. ×10^12/mL | 233 [167-306] | 284 [188-388] |
| Creatinine, mg/dL | 0.89 [0.74-1.08] | 0.86 [0.69-1.31] |
| C-reactive protein, mg/dL | 7.8 [1.5-15.3] | 14.3 [2.1-21.8] |
| Erythrocyte sedimentation rate, mm/h | 43 [20-83] | 71 [42-105] |
| Troponin ≥ 0.20 ng/mL | 40 (25.3) | 6 (7.3) |
| Treatment at presentation | | |
| Nonsteroidal antiinflammatory drugs | 116 (73.4) | 53 (64.6) |
| Colchicine | 109 (69.0) | 43 (52.4) |
| Glucocorticoids | 16 (10.1) | 13 (15.9) |
| Surgical procedure | | |
| Pericardiectomy | 2 (1.3) | 6 (7.3) |
| Pericardial window | 1 (0.6) | 6 (7.3) |
| Pericardiocentesis | 3 (1.9) | 24 (29.3) |

The data are presented as No. (%) of all cases or as median [interquartile range].
of the bone marrow, and absence of anemia may be considered as a marker of a lesser degree of inflammation associated with a better prognosis. For postcardiac injury syndromes, a decrease in hemoglobin levels may be explained by active bleeding soon after the cardiac intervention, which leads to the accumulation of hemorrhagic fluid within the pericardial sac and potentially to cardiac tamponade. This aspect has been evaluated by Kramer et al in patients with post-pericardiotomy syndrome. They reported that the disruption of the pericardial membrane due to surgery led to contamination of the pericardial fluid with hemolyzed blood and high concentrations of oxidized hemoglobin, thus increasing local oxidative stress. Possibly the surgical injury can prime RBC hemolysis, recruitment of inflammatory cells, especially neutrophils and monocytes, that release pro-oxidative and proinflammatory molecules.

Patients with idiopathic pericarditis were more likely to fail treatments and have recurrences as compared with subjects with postcardiac injury pericarditis. In this cohort, idiopathic pericarditis was more frequently diagnosed in black patients, and this is consistent with another report by Awan et al. The diagnosis of idiopathic pericarditis was less frequent in this cohort, as compared with what was found in previous studies conducted in Europe some years ago. The difference may be related to a recent increase in the number of procedures, such as atrial fibrillation ablation, pacemaker implantation, coronary artery bypass surgery, and transcatheter aortic valve implantation. Postcardiac injury pericarditis can be complicated by recurrences, cardiac tamponade, and constrictive evolution; however, the reported incidence is lower than that of idiopathic pericarditis. The etiopathogenesis of postcardiac injury pericarditis is not completely understood, but it is likely to be also an immune-mediated response to injuries deriving from the procedures. The initial pericardial injury secondary to ischemia (post-myocardial infarction pericarditis) or to physical or chemical trauma (pericarditis following cardiac procedures) may elicit an exaggerated inflammatory response in predisposed individuals.

The higher observed incidence of treatment failure or pericarditis recurrence in patients with idiopathic forms may rely on the differences in underlying pathogenesis or in the time to antiinflammatory pharmacotherapy. A shorter time to treatment is expected for postcardiac injury syndromes possibly attributable to scheduled follow-ups that allow for early identification and subsequently early modulation of the inflammatory burden. In contrast, patients with idiopathic pericarditis develop the symptoms in the outpatient setting without ready access to clinicians and are therefore expected to have an extended time-to-diagnosis and antiinflammatory treatment. Additionally, although both idiopathic and postcardiac injury pericarditis can share a similar common inflammatory response, the molecular mechanisms initiating this response may not...
be the same, which highlights the need for investigations of tailored therapies.

Patients with elevation in troponin I levels were found to have a lower risk for the development of recurrences and of the adverse composite outcome. The detection of increased troponin I levels in patients with pericarditis is an expression of the concomitant involvement of the subepicardial myocardium in the inflammatory process as well as ECG abnormalities. In contrast to coronary artery disease, the elevation in troponin levels in the serum is not a negative prognostic marker in patients with pericarditis. Imazio and colleagues had previously described that recurrences were more frequent in cases with “isolated” pericarditis with normal troponin I levels, as compared with those with myopericarditis or perimyocarditis with elevated troponin I levels. The data presented herein confirm and enlarge previous findings as they expand to a multi-ethnic population of patients in United States, including

Figure 3 – A, Treatment failure or clinical recurrences in idiopathic and postcardiac injury pericarditis. The column chart shows the incidence of treatment failure or clinical recurrences in patients with idiopathic pericarditis and postcardiac injury pericarditis. B, Adverse outcome in patients with and without troponin I positivity. The column chart shows the incidence of adverse outcome in patients with and without troponin I positivity.
a significant proportion of black patients. We also found that patients with abnormal troponin I levels more frequently presented with heart failure signs and symptoms, and yet they had more favorable outcomes in terms of pericarditis, than those without troponin I elevation. Myopericardial inflammatory syndromes, in which the inflammation involves both the pericardium and the myocardium, may have different clinical and prognostic characteristics compared with “isolated” pericarditis, and therefore tailored therapies may be required.30 In this view, troponin I level determination should be considered in every patient with a suspicion of pericarditis to correctly diagnose perimyocarditis, myopericarditis, and “isolated” pericarditis to help risk stratify the patients.31 Possibly elevated troponin I levels are simply a surrogate for a type of pericarditis or a cause of pericarditis associated with reduced recurrences (ie, postcardiac injury). Distinct ICD codes for myocarditis and pericarditis are currently used, and in this cohort we considered the I30 code for pericarditis and thoroughly reviewed to verify the correspondence between the ICD-10 code (I30) and the clinical diagnosis. Although we are well aware that it is unlikely to have missed cases of pericarditis, we may have missed some cases of pericarditis in which myocardium was secondarily involved. Pericarditis and myocarditis may have some overlapping aspects and represent diverse manifestations in the spectrum of the same disease.

Hospitalization for acute pericarditis is recommended for patients with poor prognostic characteristics (eg, subacute onset, fever, cardiac tamponade, large pericardial effusion, oral anticoagulation therapy),1 whereas low-risk cases may be safely managed in the outpatient setting.33 Although our cohort is relatively young, the high number of hospitalizations for the first episode of acute pericarditis may reflect the burden of comorbidities of the population served at this large urban hospital.

Surgical procedures related to the pericardial disease include pericardiocentesis, pericardial window, and pericardiectomy. Pericardiocentesis and pericardial window are necessary in case of cardiac tamponade or in near tamponade.34 Pericardiectomy, instead, is performed to treat constrictive pericarditis or as fourth-line therapy in patients with multiple recurrences unresponsive to medical treatments.20,35 Accordingly, pericardial surgical procedures were more frequent in the group of patients with adverse outcomes.

Several cases of death occurred in our cohort but none attributed specifically to pericarditis. Indeed, acute pericarditis is generally associated with a rather low disease-specific mortality, although patients with pericarditis appear to have an increased risk of in-hospital mortality.4 The mechanisms of this association are unexplored, because the data derive from large epidemiologic studies.1 Death is more likely to occur in patients affected by severe comorbidities, and this correlation may be explained by other underlying processes or procedure complications (ie, sepsis).36

Study Strengths and Limitations

There are several strengths in our study. First of all, the study differs from other studies in the field given the diagnostic accuracy guaranteed by a chart-level review. We meticulously reviewed each case to confirm the diagnosis of pericarditis and only included those subjects meeting the 2015 ESC guideline criteria.1 This aspect is particularly important considering that recently ICD codes for pericarditis were found to be unreliable for pericarditis diagnosis.37 Second, we were able to longitudinally evaluate the natural history and the complications. Third, we studied a population that included a significant number of black patients who are underrepresented in other series, thus yielding a higher diversity compared with other previously reported populations.14,24,28 Some limitations, however, should be acknowledged. First, despite the use of unbiased tools for the initial cohort identification of cases, it remains a retrospective study with potential selection bias and ascertainment bias related to missing data (ie, biomarkers), therefore limiting our conclusions. Second, it is a single-center study, although conducted in a large hospital serving different groups of patients, whose population is characterized by an important burden of comorbidities and experienced a high rate of hospitalization, thus partially limiting the generalization of the results. Third, the follow-up was limited to approximately 6 months, and possibly some complications, particularly the development of constrictive pericarditis, were not captured, also because the electronic health records only documented events from the main hospital and in-network clinics. We only used the ICD-10 code I30 and the corresponding ICD-9 codes to retrieve the cases for this study, and we may have missed some cases of pericarditis with secondary involvement of the myocardium in the inflammatory process, thus limiting the conclusions that can be made on patients with acute pericarditis and troponin
elevation. We did not perform any adjustment for multiple tests when comparing groups, because these analyses were only meant to unravel possible differences among patients’ groups. Finally, we were not able to record the exact time to event for all patients; therefore, we could not model a survival analysis accounting for different follow-up times.

Conclusion
Acute pericarditis, although mostly a self-limiting disease, is associated with a clinically significant rate of complications. Acute idiopathic and postcardiac injury pericarditis should be considered as two different entities, with separate mechanisms driving the disease, different complication profiles, and different natural histories of the disease. The measurement of serum troponin I levels could be useful to recognize patients with elevated levels who are paradoxically at lower risk of failure of treatment, recurrences, constrictive pericarditis, tamponade, or death. However, how to tailor the treatment plan for those with abnormal troponin I values remains unclear. Further prospective studies are warranted to better define the time window and characteristic of subacute onset of pericarditis and may aid in identifying pathophysiological mechanisms of and targeted therapy for idiopathic and postcardiac injury pericarditis.

Acknowledgments
Author contributions: A. V. and J. G. C. performed the chart review. M. S. D. and T. S. G. provided the informatic support. J. G. C. and A. A. reviewed the ECG and echocardiographic data. A. V., J. G. C., and M. D. analyzed data and wrote the manuscript. A. A. gave suggestions during the writing of the manuscript. A.Bo., A. G. M., G. W., B. W. V. T., D. H. B., F. M., A. Beu., and J. F. P. critically revised the manuscript. All authors approved the final version of the manuscript. A. V. and A. A. are the guarantors of this work and, as such, have full access to all data in the study and take responsibility for the integrity of data and the accuracy of data analysis.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: The current study was supported in part by an investigator-initiated study from Kiniksa Pharmaceuticals Ltd. to T. S. G. A. Bo. and J. F. P. report being employees of Kiniksa Pharmaceuticals Ltd. as potential conflict of interests for the study. A. Bo. And A. V. received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 American Heart Association Scientific Sessions (Philadelphia, PA). A. A. has served as a consultant to Kiniksa Pharmaceuticals Ltd. None declared (J. G. C., M. S. D., A. G. M., G. W., B. W. V. T., D. H. B., F. M.).

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

Additional information: The e-Tables and e-Figure can be found in the Supplemental Materials section of the online article.

References
1. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964.
2. Chiabrando JG, Bonaventura A, Vecchie A, et al. Management of acute and recurrent pericarditis: JACC, State-of-the-Art Review. J Am Coll Cardiol. 2020;75(1):76-92.
3. Imazio M, Cecchi E, Demichels B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498-501.
4. Kyto V, Sipila J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130(18):1601-1606.
5. Noubiap JJ, Agbor VN, Ndoadoungue AL, et al. Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart. 2019;105(3):180-188.
6. Imazio M, Hoit BD. Post-cardiac injury syndromes: an emerging cause of pericardial diseases. Int J Cardiol. 2013;168(2):648-652.
7. Bonaventura A, Montecucco F. Inflammation and pericarditis: Are neutrophils actors behind the scenes? J Cell Physiol. 2019;234(5):5390-5398.
8. Brucato A, Valenti A, Maisch B. Acute and recurrent pericarditis: still idiopathic? J Am Coll Cardiol. 2017;69(22):2775.
9. Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):46-53.
10. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-2099.
11. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PeRicarditis (COPE) trial. Circulation. 2005;112(13):2012-2016.
12. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-414.
13. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-2237.
14. Imazio M, Brucato A, Barbieri A, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation. 2013;128(1):42-49.
15. Gamaiza-Chulian S, Leon-Jimenez J, Recuerda-Nunez M, Camacho-Freire S, Gutierrez-Barrios A, Vargas-Machuca JC. Cardiac troponin-T in acute pericarditis. J Cardiovasc Med (Hagerstown). 2014;15(1):68-72.
16. https://www.trinetx.com/. Accessed October 17, 2020.
17. https://www.trinetx.com/news-and-events#publications. Accessed October 17, 2020.
18. Imazio M, Cecchi E, Demichels B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21): 2739-2744.
19. Weitzman LB, Tinker WP, Kronzon I, Cohen ML, Glassman E, Spencer FC. The incidence and natural history of pericardial effusion after cardiac surgery: an echocardiographic study. Circulation. 1984;69(3):506-511.
20. Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015;314(14):1498-1506.
21. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50.
22. Kramer PA, Chacko BK, Ravi S, et al. Hemoglobin-associated oxidative stress in the pericardial compartment of postoperative cardiac surgery patients. Lab Invest. 2015;95(2):132-141.

23. Butts B, Goeddel LA, George DJ, et al. Increased inflammation in pericardial fluid persists 48 hours after cardiac surgery. Circulation. 2017;136(23):2284-2286.

24. Awan A, Tiruneh F, Wessly P, et al. Acute pericarditis: descriptive study and etiology determination in a predominantly African American population. Cureus. 2017;9(7):e1431.

25. Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol. 1995;75(5):378-382.

26. Zheng MF, Wang Z, Bao ZY. Myocardial injury and pericarditis after combined left atrial and coronary sinus ablation in Wolff-Parkinson-White syndrome: a case report. BMC Cardiovasc Disord. 2020;20(1):18.

27. Gao Y, Bishopric NH, Chen HW, Li JT, Huang YL, Huang HX. Post-cardiac injury syndrome in acute myocardial infarction patients undergoing PCE: a case report and literature review. BMC Cardiovasc Disord. 2018;18(1):234.

28. Imazio M, Brucato A, Rovere ME, et al. Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol. 2011;108(8):1183-1187.

29. Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev. 2015;14(2):90-97.

30. Imazio M. Pericarditis with troponin elevation: is it true pericarditis and a reason for concern? J Cardiovasc Med (Hagerstown). 2014;15(1):73-77.

31. Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol. 2003;42(12):2144-2148.

32. Imazio M, Brucato A, Spodick DH, Adler Y. Prognosis of myopericarditis as determined from previously published reports. J Cardiovasc Med (Hagerstown). 2014;15(12):835-839.

33. Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol. 2004;43(6):1042-1046.

34. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186-1197.

35. Syed FF, Schaff HV, Oh JK. Constrictive pericarditis: a curable diastolic heart failure. Nat Rev Cardiol. 2014;11(9):530-544.

36. Kumar N, Pandey A, Jain P, Garg N. Acute pericarditis-associated hospitalization in the USA: a nationwide analysis, 2003-2012. Cardioiology. 2016;135(1):27-35.

37. Furqan MM, Chetrit M, Cremer P, Klein AL. Abstract 15826: Misclassification of pericardial disease diagnosis: International Classification of Diseases-10 coding requires validation. Circulation. 2019;140(Suppl_1). A15826-A15826.